Table 1 Patient clinical characteristics
Patients | Age/Gender (M/F) | Stage | Histology* | Lesion§ | Performance status (ECOG) | Peptides†| Dose (mg) | Phase of treatment (Prior therapy**) |
|---|---|---|---|---|---|---|---|---|
1 | 54/M | Recurrence | AD | LN, bone | 2 | L, T, R1, R2 | 0.5 | 5th (PLT, RT) |
2 | 48/M | IIIB | AD | PM, effusion | 2 | L, T, R1, R2 | 0.5 | 5th (PLT) |
3 | 65/M | Recurrence | AD | PM | 2 | L, T, R1, R2 | 0.5 | 6th (PLT, EGFR-TKI) |
4 | 58/M | IV | AD | Primary, bone | 2 | L, T, R1, R2 | 1 | 4th (PLT) |
5 | 60/M | IV | AD | Primary, LN | 1 | L, T, R1, R2 | 1 | 3rd (PLT) |
6 | 47/M | IV | AD | Primary, LN, ADR | 0 | L, T, R1, R2 | 1 | 3rd(PLT, RT) |
7 | 40/M | IIIA | AD | Primary, LN | 1 | L, T, R1, R2 | 3 | 3rd(PLT) |
8 | 69/M | Recurrence | SQ | PM | 1 | L, T, R1, R2 | 3 | 3rd(PLT, RT) |
9 | 65/M | Recurrence | AD | Dissemination | 0 | L, T, R1, R2 | 3 | 2nd(PLT, RT) |
10 | 57/M | Recurrence | PLEO | LN | 1 | L, C, R1, R2 | 1 | 3rd(PLT, RT) |
11 | 55/F | IIIB | AD | Primary, LN, effusion | 2 | L, C, R1, R2 | 1 | 5th(PLT, EGFR-TKI) |
12 | 62/M | Recurrence | AD | PM | 1 | L, C, R1, R2 | 1 | 2nd(PLT) |
13 | 68/F | IV | AD | Primary, bone, effusion | 2 | L, C, R1, R2 | 3 | 2nd(PLT) |
14 | 39/F | IV | NSCLC | Primary, liver, bone | 2 | L, C, R1, R2 | 3 | 2nd(PLT, RT) |
15 | 61/M | Recurrence | AD | PM, LN | 1 | L, C, R1, R2 | 3 | 5th(PLT, RT, EGFR-TKI) |